Merck Millipore's Strat-M Membrane as Effective as Skin for Permeation Studies
Merck Millipore has announced publication of a study showing that its Strat-M synthetic membrane predicts skin permeation of chemical compounds during in vitro transdermal diffusion studies as effectively as human or animal skin. The study was conducted by researchers at Josai University in Japan and published in the 25 January 2015 issue of European Journal of Pharmaceutical Sciences.
Strat-M membrane is a synthetic, non-animal-based model that is predictive of diffusion in human skin for a wide range of compounds and formulations, including active pharmaceutical ingredients, cosmetic actives, personal care products, pesticides and other chemicals. The membrane provides highly consistent, reproducible diffusion data without the lot-to-lot variability that often occurs with biological models.
The new study evaluated the ability of Strat-M membrane to serve as an alternative to human and animal skin for estimating the skin permeability of different chemical compounds. Thirteen compounds were tested on excised human skin, hairless rat skin and Strat-M membrane. Permeability coefficients obtained with Strat-M membrane could be used to predict those obtained from the human and rat skins.
"In vitro skin permeation studies are essential to development of new transdermal delivery systems," said Kenji Sugibayashi, author of the study, Professor of Pharmaceutical Sciences at Josai University, and renowned expert on skin permeation. "Biological models are often used to conduct this research, but there are various drawbacks, including high variability, low availability, safety considerations and storage limitations." Study co-author Dr Hiroaki Todo added: "Our study suggests that Strat-M membrane can serve as an alternative to human and animal skin in permeation studies, offering researchers a valuable tool for screening candidate compounds."
"Drs Sugibayashi's and Todo's peer-reviewed research confirms that Strat-M membrane can be used for transdermal diffusion testing," said Patrick Schneider, Head of Bioscience at Merck Millipore. "Published results supporting the membrane's application will increase awareness and accelerate adoption by the research community, facilitating in vitro testing of transdermal formulations."
Introduced in 2012, Strat-M membrane is constructed of multiple layers, creating morphology similar to human skin. Strat-M membrane is individually packaged as precut discs that are easy to store and do not need to be hydrated prior to use.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance